{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:19:14Z","timestamp":1759940354817,"version":"3.40.3"},"reference-count":31,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,5,21]],"date-time":"2012-05-21T00:00:00Z","timestamp":1337558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vet Pharm &amp; Therapeutics"],"published-print":{"date-parts":[[2012,10]]},"abstract":"<jats:p>Clark, M. H., Hoenig, M., Ferguson, D. C., Dirikolu, L. Pharmacokinetics of pioglitazone in lean and obese cats.<jats:italic>J. vet. Pharmacol. Therap.<\/jats:italic>\u00a0<jats:bold>35<\/jats:bold>, 428\u2013436.<\/jats:p><jats:p>Pioglitazone is a thiazolidinedione insulin sensitizer that has shown efficacy in Type 2 diabetes and nonalcoholic fatty liver disease in humans. It may be useful for treatment of similar conditions in cats. The purpose of this study was to investigate the pharmacokinetics of pioglitazone in lean and obese cats, to provide a foundation for assessment of its effects on insulin sensitivity and lipid metabolism. Pioglitazone was administered intravenously (median 0.2\u2003mg\/kg) or orally (3\u2003mg\/kg) to 6 healthy lean (3.96\u2003\u00b1\u20030.56\u2003kg) and 6 obese (6.43\u2003\u00b1\u20030.48\u2003kg) cats, in a two by two Latin Square design with a 4\u2010week washout period. Blood samples were collected over 24\u2003h, and pioglitazone concentrations were measured via a validated high\u2010performance liquid chromatography assay. Pharmacokinetic parameters were determined using two\u2010compartmental analysis for IV data and noncompartmental analysis for oral data. After oral administration, mean bioavailability was 55%,<jats:italic>t<\/jats:italic><jats:sub>1\/2<\/jats:sub>was 3.5\u2003h, T<jats:sub>max<\/jats:sub>was 3.6\u2003h, C<jats:sub>max<\/jats:sub>was 2131\u2003ng\/mL, and AUC<jats:sub>0\u2013\u221e<\/jats:sub>was 15 556 ng\/mL\u00b7h. There were no statistically significant differences in pharmacokinetic parameters between lean and obese cats following either oral or intravenous administration. Systemic exposure to pioglitazone in cats after a 3\u2003mg\/kg oral dose approximates that observed in humans with therapeutic doses.<\/jats:p>","DOI":"10.1111\/j.1365-2885.2011.01341.x","type":"journal-article","created":{"date-parts":[[2012,5,22]],"date-time":"2012-05-22T02:29:34Z","timestamp":1337653774000},"page":"428-436","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacokinetics of pioglitazone in lean and obese cats<sup>1<\/sup>"],"prefix":"10.1111","volume":"35","author":[{"given":"M. H.","family":"CLARK","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"HOENIG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. C.","family":"FERGUSON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"DIRIKOLU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,5,21]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_6_2_1","DOI":"10.1111\/j.1463-1326.2008.00926.x"},{"doi-asserted-by":"publisher","key":"e_1_2_6_3_1","DOI":"10.1002\/9780470690567.ch2"},{"doi-asserted-by":"publisher","key":"e_1_2_6_4_1","DOI":"10.1210\/jc.2009-0911"},{"doi-asserted-by":"publisher","key":"e_1_2_6_5_1","DOI":"10.1056\/NEJMoa060326"},{"doi-asserted-by":"publisher","key":"e_1_2_6_6_1","DOI":"10.1111\/j.1939-1676.2000.tb01494.x"},{"doi-asserted-by":"publisher","key":"e_1_2_6_7_1","DOI":"10.1046\/j.1365-2125.2003.01785.x"},{"doi-asserted-by":"publisher","key":"e_1_2_6_8_1","DOI":"10.1016\/0041-008X(65)90122-5"},{"doi-asserted-by":"publisher","key":"e_1_2_6_9_1","DOI":"10.1055\/s-2000-8525"},{"unstructured":"European Medicines Agency. (2004)Actos: European Public Assessment report\u2010scientific discussion. Available athttp:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Scientific_Discussion\/human\/000285\/WC500021381.pdf. Accessed March 22 2011.","key":"e_1_2_6_10_1"},{"doi-asserted-by":"publisher","key":"e_1_2_6_11_1","DOI":"10.1016\/S1532-0456(03)00194-7"},{"doi-asserted-by":"publisher","key":"e_1_2_6_12_1","DOI":"10.1016\/S0303-7207(02)00264-2"},{"doi-asserted-by":"publisher","key":"e_1_2_6_13_1","DOI":"10.1097\/01.mco.0000241668.30761.69"},{"doi-asserted-by":"publisher","key":"e_1_2_6_14_1","DOI":"10.2460\/ajvr.2003.64.1409"},{"doi-asserted-by":"publisher","key":"e_1_2_6_15_1","DOI":"10.1152\/ajpregu.00313.2006"},{"doi-asserted-by":"publisher","key":"e_1_2_6_16_1","DOI":"10.1007\/s00125-005-0070-x"},{"key":"e_1_2_6_17_1","first-page":"156","article-title":"Effects of pioglitazone on glucose and lipid metabolism in normal and insulin\u2010resistant animals","volume":"40","author":"Ikeda H.","year":"1990","journal-title":"Arzneimittel-Forschnung\/Drug Research"},{"doi-asserted-by":"publisher","key":"e_1_2_6_18_1","DOI":"10.1016\/j.domaniend.2008.05.008"},{"doi-asserted-by":"publisher","key":"e_1_2_6_19_1","DOI":"10.1111\/j.1365-2125.2007.02986.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0090-9556(25)07523-3","article-title":"Disposition and metabolism of the hypoglycemic agent pioglitazone in rats","volume":"22","author":"Krieter P.A.","year":"1994","journal-title":"Drug Metabolism and Disposition"},{"doi-asserted-by":"publisher","key":"e_1_2_6_21_1","DOI":"10.1016\/j.cell.2005.11.026"},{"key":"e_1_2_6_22_1","first-page":"29","article-title":"Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys","volume":"47","author":"Maeshiba Y.","year":"1997","journal-title":"Arzneimittel-Forschung\/Drug Research"},{"doi-asserted-by":"publisher","key":"e_1_2_6_23_1","DOI":"10.2460\/ajvr.2000.61.775"},{"doi-asserted-by":"publisher","key":"e_1_2_6_24_1","DOI":"10.1093\/jn\/128.12.2747S"},{"doi-asserted-by":"publisher","key":"e_1_2_6_25_1","DOI":"10.1152\/ajpendo.00522.2004"},{"doi-asserted-by":"publisher","key":"e_1_2_6_26_1","DOI":"10.2337\/db07-1828"},{"doi-asserted-by":"publisher","key":"e_1_2_6_27_1","DOI":"10.1080\/0049825031000085951"},{"doi-asserted-by":"publisher","key":"e_1_2_6_28_1","DOI":"10.1007\/BF00423041"},{"key":"e_1_2_6_29_1","first-page":"263","article-title":"Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats","volume":"40","author":"Sugiyama Y.","year":"1990","journal-title":"Arzneimittel-Forschung\/Drug Research"},{"doi-asserted-by":"publisher","key":"e_1_2_6_30_1","DOI":"10.1111\/j.1365-2885.2010.01217.x"},{"doi-asserted-by":"publisher","key":"e_1_2_6_31_1","DOI":"10.1016\/S1570-0232(03)00575-0"},{"doi-asserted-by":"publisher","key":"e_1_2_6_32_1","DOI":"10.1016\/0731-7085(95)01665-1"}],"container-title":["Journal of Veterinary Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2885.2011.01341.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2885.2011.01341.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T13:28:49Z","timestamp":1743168529000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2885.2011.01341.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,21]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["10.1111\/j.1365-2885.2011.01341.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2885.2011.01341.x","archive":["Portico"],"relation":{},"ISSN":["0140-7783","1365-2885"],"issn-type":[{"type":"print","value":"0140-7783"},{"type":"electronic","value":"1365-2885"}],"subject":[],"published":{"date-parts":[[2012,5,21]]}}}